News from patient groups Psychodermatology Network MDT meetings 75th Dowling Club Anniversary
SPRING 2022
The BAD Annual Meeting returns to in-person format this July
Demonstrated sustained relief in Psoriasis at 5 years and in Psoriatic Arthritis at 2 years*1,2
COMPLETE SKIN CLEARANCE • At Week 16: PASI 100 achieved in more than 1/3 of PsO patients treated with TREMFYA®.†3 • Long term: PASI 100 response rate of over 50% at Week 52 sustained at 5 years in PsO patients treated with TREMFYA®.‡1
RAPID JOINT EFFICACY • At Week 4: ACR20 achieved in 20% of PsA patients treated with TREMFYA®. 2 • Long term: 74% ACR20 response rate seen at 1 year and sustained at 2 years in PsA patients treated with TREMFYA®.¶2,4
PROVEN DURABILITY • Most patients who started on TREMFYA®, stayed on TREMFYA® long-term. 2,5
To access educational videos, clinical papers, patient support and more visit https://www.janssenmedicalcloud.co.uk/ or scan the QR code. *Sustained improvements in psoriasis disease severity (as measured by PASI 90 and PASI 100 scores) and sustained improvements in psoriatic arthritis disease severity (as measured by ACR scores, HAQ-DI scores and resolution of enthesitis and dactylitis).1,2 †PASI 100 analysis not part of the statistical analysis plan. 37.4% of patients treated with TREMFYA® achieved PASI 100 at Week 16 (n=329) vs 0.6% of patients treated with placebo (n=174; p